Axsome Therapeutics AXSM Intangibles (Net)
Intangibles (Net) at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IntangibleAssetsNetExcludingGoodwill.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's intangibles (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's intangibles (net)?
- Axsome Therapeutics (AXSM) reported intangibles (net) of $38.95M in Q1 2026.
- How has Axsome Therapeutics's intangibles (net) changed year-over-year?
- Axsome Therapeutics's intangibles (net) decreased by 14.1% year-over-year, from $45.32M to $38.95M.
- What is the long-term trend for Axsome Therapeutics's intangibles (net)?
- Over 3 years (2022 to 2025), Axsome Therapeutics's intangibles (net) has grown at a -12.1% compound annual growth rate (CAGR), from $59.66M to $40.52M.
- What does intangibles (net) mean?
- The value of non-physical assets like patents and licenses, minus amortization.
- How do you interpret intangibles (net)?
- An increase typically reflects the acquisition or development of new intellectual property, while a decrease reflects ongoing amortization.
- How does intangibles (net) compare across companies?
- High intangible asset value is a hallmark of successful biopharma companies with strong patent portfolios.